

ISCTM Session 4A:
**Clinical Trials in Autism Spectrum
Disorders: Methods, Measurements,
Designs, and Outcomes**

Co-Chairs:

Doug Feltner, M.D, consultant
Joe Horrigan, M.D., VP, Neuren

Disclosures

■ Doug Feltner:

- Consulting:
 - Afferent, AgeneBio, Astellas, Baxter, Biotech Venture Fund, Dark Canyon Pharma, Embera Neurotherapeutics, EnVivo, InVentages, Ironwood Pharma, JNJ, Merck, MMS Holdings, New Leaf Venture, Ono, Rhine Pharma, Roche, SAGE, Satori, Soffinova, Taisho, Takeda, Third Rock Venture, Toyama,
- Grant Reviews:
 - NINDS, NIMH
- Equity:
 - Embera Neurotherapeutics, Pfizer, Inc.
- Former employee:
 - Solvay, Parke-Davis, Pfizer Inc.

Introduction to the Session

- Overview of Autism Spectrum and clinical targets for treatment
- Challenges in designing and implementing ASD clinical trials
- Translational methods to improve success
- Two development programs
- Questions after talks and panel discussion at end

Questions to Consider

- What are the best study designs?
- What have we learned from the design and conduct of past studies?
- Will translational methods improve success rates and efficiency?
- Why so much clinical trials activity in the autism spectrum now?